0      0

LV04 - Advancing Precision-Targeted Treatment for Patients with Metastatic Non-Small Cell Lung Cancer

‐ Nov 10, 2023 12:15pm


Tajuana Bradley has served on speakers bureaus for ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Coherus, G1 Therapeutics, Puma Biotechnology, and Seagen.

Learning Objectives:

  • Evaluate pivotal clinical trials leading to recent FDA approvals of new molecular targeted treatment options for patients with metastatic non-small cell lung cancer (NSCLC), and related updates to clinical practice guidelines.
  • Differentiate recently validated predictive and prognostic biomarkers and their clinical relevance for treating patients with mNSCLC.
  • Integrate evidence-based best practices for monitoring and managing adverse events associated with molecular targeted and combination therapies for patients with mNSCLC.
  • these are already done


You must be logged in and own this session in order to post comments.